1.  Your lab is set up like a miniature industry facility. How do you see the relationship between an academic center like this and industry at large?

    My work in previous jobs has been with pharmaceutical companies, and I know they would never send an interesting compound out of their walls. They might send a related one that has failed. They have to be very careful with their intellectual property.

    Our work here applies to an earlier stage, a discovery stage. A lot of faculty here have start-ups. In some cases, we are helping them get the data to decide whether there is a potential therapeutic. They might be researching a disease without a treatment, so demonstrating that you can identify an interesting compound can be valuable. The Office of Cooperative Research is pretty big, and they're the technology transfer office here at Yale. Patenting small molecules is worth more to Yale in terms of actual dollars, so if someone wants to start a company or raise money, the business side could start from here. It's also potentially interesting for their research.

    I got into biotech and tool companies in 2000, around the time the human genome was completed. There was a huge investment in companies that did genomic tools. The pendulum is swinging back toward molecules and leading to potential drug treatments. But you need to have the molecule --- that is worth more in the intellectual property because you have something, it's novel, it's useful for this specific disease, you know how to find more. It's not enough to start a tool company these days.

    Another positive aspect of our relationship to industry concerns student training. Yale educates grad students and postdocs. Many people we work with may be thinking about industry, and this gives them some unique experience. When they interview at a pharmaceutical company, most people from an academic background don't know the language but the process is very similar.

2.  Does a screening center like this have any interest in competing with industry in drug discovery and application?

    I don't think it has to be a head-on competition. A lot of companies, because of financial pressures and the high cost of bringing a drug to market, have cut back on discovery. Basic researchers who had worked to find new drugs are brought into other parts of a company to add another edge. Obviously, private companies have many more compounds and are built for a totally different scale, but at the end of the day they still need new compounds, new ideas, new proteins, and new diseases. Before the orphan drug legislation, if you wanted to work on a disease that does not affect hundreds of thousands of people, it was bad business, but now the government is helping and companies are doing it successfully. A lot of that will start in academia and transition later.

3.  How are the molecules for screening libraries discovered?

    Synthetic chemists make the chemicals. Gary Strobel, father of Yale Department of Molecular Biophysics and Biochemistry professor Scott Strobel, has spent his career at the University of Utah conducting natural extractions. At my undergraduate institution there was a professor who liked to scuba dive, so he would look for novel chemicals in deep-sea sponges and then try to recreate those molecules. They tend to be very complicated: Good drugs are often small, because if they're too big we can't get them into cells. The way natural chemicals are put together is special.

    Scott Strobel received a grant last year for a four-year undergraduate course, and over spring break the class went to Peru and collected natural specimens from the rainforest. They came back and grew microorganisms that live in commensural relationships with those plants and then made extracts and developed various assays. We were able to take their extracts and put them into our plates. They were mixtures; you could isolate the different fractions and you would see activity. You'd continue to fractionate it and do mass spectrometry, and before long, you could figure out what these compounds were.

4.  That strikes me as overwhelming: the realization that there are so many compounds waiting to be discovered and that we might never find the best ones. Is there a more analytical approach to screening small molecules?

    We pay close attention to structure. With most of our screens, there are relevant substitutions only at certain types of sites and certain substituting groups, for example, iodine, fluorine, and bromine. Often a number of hits have very similar structures. The more you can survey, the more likely you'll find something, which is the whole concept of libraries and miniaturization.

    One example we've worked on is methotrexate and the protein dihydrofolatereductase, which is involved in thymidine synthesis. Methotrexate is a drug that looks a lot like folic acid's metabolite. We're trying to bind fluorescently labeled methotrexate to the protein and then find a small molecule that kicks this out very fast. We use a tumbling difference (anisotropy) to identify active compounds, which we then subject to optimization and further screening. We didn't get many hits, but the ones we did get all have a conserved structure.

5.  Can you give me an example of a project that has originated here, and how far it has gone?

    One of my first projects here involved a young faculty member in pathology who works on a protein that makes metastases worse in cancers. Early on, I worked with him to optimize a colorimetric assay, which performed very well, but we only had a few hits from our library. He collaborated with an enzyme kinetics expert to characterize the competitiveness of the interactions further and patented a few things out of that.

    The National Cancer Institute has a lot of compounds and since his project was associated with cancer, this researcher received about 2,000 compounds from the institute; we helped with the screening. He had a number of hits from the primary screening showing good dose-response, and he is now interested in seven of these. The new assay is much more biologically relevant than the previous way they were testing it; there is potential for licensing. Even though he studies a protein and its molecular structure, collaborations like these enable him to work more broadly, and this kind of screening is complementary to other methods.

6.  How far away is this project from clinical use, if everything goes right?

    This researcher filed for a provisional patent for the early screen. If you license it to someone who wants to develop it, such as a pharmaceutical company, it takes a while --- and a lot of money and time. It takes years and years.

7.  Have you had someone bring something from the bedside into the lab?

    Yes, we did. It was an endocrinology project. We screened a primary cell line derived from a patient who had a very bizarre tumor that expressed parathyroid hormone, but in the pancreas. The patient had abnormal calcium levels in the blood, standard treatments failed, and the patient died. They took tumor cells and made a cell line with the PTH promoter behind fireﬂy luciferase to understand what inﬂuenced expression in this extraordinary case.

8.  What is the next evolutionary step for your field?

    High-content screening is a huge growth area. You get complex images with multiple forms of information. This is different from high-throughput screening --- which we currently do --- in which you get a single scalar value for each well. More of these imaging systems are available; a lot of detection reagents have been around for a long time (antibodies, stains for immunofluorescence, flow cytometry, etc.). The software has been used to quantify features in microscopy. We're just doing this a lot more --- and faster.

    Let's say you identify a drug here and you want to look at different cell types or you want to do dose-response of a hundred compounds. In a cell-based assay, you can quickly get to hundreds of thousands of samples, where this method is valuable. A lot of people do ADMETox (absorbtion, distribution, metabolism, and excretion) assays, and the complex information is useful downstream in cell-based systems.

    Another development is increasing miniaturization. Companies who were doing 384-well formats are now doing 1,536. New liquid dispensing technologies use vibration and sound waves. When you get that small, new methods are needed to increase reproducibility and manage the very high variability.

    With miniaturization, the idea is to increase survey space. Companies are always adding to their compounds; they have huge medicinal chemistry groups that are always growing. Sometimes pharmaceutical companies rescreen entire libraries to keep their assays current.

9.  Will some of your techniques be useful in the clinic? What kinds of technological breakthroughs need to happen for some of these ideas to be applied?

    I think so. On the epidemiological level, there will be patient stratification based on response to treatments and tailored diagnosis. A lot of that will depend on genome sequence information or even tumor type expression. Estrogen receptors on the surface will lead to a different treatment regimen than for someone whose tumors don't express such receptors. I think these techniques will grow in steps.

    How much these types of things influence what drugs get developed and how they get marketed and distributed is not known. The NIH is discussing pharmacogenics with biotech and pharmaceutical companies, in which a drug that's targeted to particular patient populations is sold with a diagnostic to differentiate patients. A lot of tool companies are poising themselves in the diagnostics field.

    I don't know how much high-throughput will apply directly as far as the actual techniques of personalized medicine. It will be genomically based, gathering DNA and RNA from blood. That will happen sooner. Only later will someone study a variant of something, a kinase that's produced in people with a certain type of cancer, and with these techniques you could look for inhibitors.
